The treatment of multiple myeloma (MM) has undergone a significant paradigm shift in the last 20 years, from conventional chemotherapy to more tumor-specific treatments, based on the interference with pathogenesis of the malignant clone as well as the bone microenvironment [...].

Babak Myeloma Group Department of Pathological Physiology Faculty of Medicine Masaryk University 625 00 Brno Czech Republic

Department of Hemato Oncology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc 779 00 Olomouc Czech Republic

Zobrazit více v PubMed

Singhal S., Mehta J. Thalidomide for relapsed or refractory myeloma. In: Chanan-Khan A.A., editor. Immunomodulating Drugs for the Treatment of Cancer. Lippincott Williams and Wilkins; Baltimore, MD, USA: 2011. pp. 51–60.

Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., et al. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. N. Engl. J. Med. 1999;341:1565–1571. doi: 10.1056/nejm199911183412102. PubMed DOI

Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., Badros A., Zangari M., Anaissie E., Epstein J., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492–494. doi: 10.1182/blood.v98.2.492. PubMed DOI

Glasmacher A., Hahn C., Hoffmann F., Naumann R., Goldschmidt H., Lilienfeld-Toal M., Orlopp K., Schmidt-Wolf I., Gorschlüter M. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 2006;132:584–593. doi: 10.1111/j.1365-2141.2005.05914.x. PubMed DOI

Fermand J.-P., Jaccard A., Macro M., Uzunhan Y., Allard C., Castaigne S., Divine M., Mariette X., Leblond V., Chevret S. A Randomized Comparison of Dexamethasone + Thalidomide (Dex/Thal) vs Dex + Placebo (Dex/P) in Patients (pts) with Relapsing Multiple Myeloma (MM) Blood. 2006;108:3563. doi: 10.1182/blood.v108.11.3563.3563. DOI

Palumbo A., Bringhen S., Caravita T., Merla E., Capparella V., Callea V., Cangialosi C., Grasso M., Rossini F., Galli M., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet. 2006;367:825–831. doi: 10.1016/s0140-6736(06)68338-4. PubMed DOI

Attal M., Harousseau J.-L., Leyvraz S., Doyen C., Hulin C., Benboubker L., Yakoub-Agha I., Bourhis J.-H., Garderet L., Pegourie B., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–3294. doi: 10.1182/blood-2006-05-022962. PubMed DOI

Abdelkefi A., Ladeb S., Torjman L., Ben Othman T., Lakhal A., Ben Romdhane N., El Omri H., Elloumi M., Belaaj H., Jeddi R., et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial. Blood. 2008;111:1805–1810. doi: 10.1182/blood-2007-07-101212. PubMed DOI

Zemanova M., Scudla V., Adam Z., Gregora E., Pour L., Minarik J., Pavlicek P., Pika T., Bacovsky J. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. Neoplasma. 2008;55:345–349. PubMed

Lokhorst H.M., Schmidt-Wolf I., Sonneveld P., Van Der Holt B., Martin H., Barge R., Bertsch U., Schlenzka J., Bos G.M., Croockewit S., et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008;93:124–127. doi: 10.3324/haematol.11644. PubMed DOI

Morgan G.J., Davies F.E., Gregory W.M., Bell S.E., Szubert A.J., Coy N.N., Cook G., Feyler S., Johnson P.R.E., Rudin C., et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012;97:442–450. doi: 10.3324/haematol.2011.043372. PubMed DOI PMC

Zervas K., Mihou D., Katodritou E., Pouli A., Mitsouli C., Anagnostopoulos A., Delibasi S., Kyrtsonis M., Terpos E., Zikos P., et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: Results of a multicenter randomized trial of the Greek myeloma study group. Ann. Oncol. 2007;18:1369–1375. doi: 10.1093/annonc/mdm178. PubMed DOI

Minarik J., Sandecka V., Maisnar V., Gregora E., Spicka I., Starostka D., Plonkova H., Jarkovsky J., Walterová L., Wróbel M., et al. 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group. Leuk. Res. 2013;37:1063–1069. doi: 10.1016/j.leukres.2013.06.019. PubMed DOI

Krejci M., Gregora E., Straub J., Minarik J., Scudla V., Adam Z., Krivanova A., Pour L., Zahradova L., Buchler T., et al. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. Ann. Hematol. 2011;90:1441–1447. doi: 10.1007/s00277-011-1206-3. PubMed DOI

Mileshkin L., Stark R., Day B., Seymour J.F., Zeldis J.B., Prince H.M. Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring. J. Clin. Oncol. 2006;24:4507–4514. doi: 10.1200/jco.2006.05.6689. PubMed DOI

Kumar S., Rajkumar S.V. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur. J. Cancer. 2006;42:1612–1622. doi: 10.1016/j.ejca.2006.04.004. PubMed DOI

D’Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 1994;91:4082–4085. doi: 10.1073/pnas.91.9.4082. PubMed DOI PMC

Anderson K.C. Lenalidomide and Thalidomide: Mechanisms of Action—Similarities and Differences. Semin. Hematol. 2005;42:S3–S8. doi: 10.1053/j.seminhematol.2005.10.001. PubMed DOI

Stephens T.D., Bunde C.J., Fillmore B.J. Mechanism of action in thalidomide teratogenesis. Biochem. Pharmacol. 2000;59:1489–1499. doi: 10.1016/s0006-2952(99)00388-3. PubMed DOI

Vallet S., Palumbo A., Raje N., Boccadoro M., Anderson K.C. Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk. Lymphoma. 2008;49:1238–1245. doi: 10.1080/10428190802005191. PubMed DOI

Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., Yamaguchi Y., Handa H. Identification of a Primary Target of Thalidomide Teratogenicity. Science. 2010;327:1345–1350. doi: 10.1126/science.1177319. PubMed DOI

Vrábel D., Vrábel D., Pour L., Pour L., Ševčíková S., Ševčíková S. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 2019;34:56–66. doi: 10.1016/j.blre.2018.11.003. PubMed DOI

Ito T., Handa H. Molecular mechanisms of thalidomide and its derivatives. Proc. Jpn. Acad. Ser. B. 2020;96:189–203. doi: 10.2183/pjab.96.016. PubMed DOI PMC

Yamanaka S., Murai H., Saito D., Abe G., Tokunaga E., Iwasaki T., Takahashi H., Takeda H., Suzuki T., Shibata N., et al. Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF. EMBO J. 2021;40:e105375. doi: 10.15252/embj.2020105375. PubMed DOI PMC

Palumbo A., Falco P., Corradini P., Falcone A., Di Raimondo F., Giuliani N., Crippa C., Ciccone G., Omedè P., Ambrosini M.T., et al. Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network. J. Clin. Oncol. 2007;25:4459–4465. doi: 10.1200/jco.2007.12.3463. PubMed DOI

Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E.A., Siegel D., Borrello I., Rajkumar S.V., Chanan-Khan A.A., et al. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. N. Engl. J. Med. 2007;357:2133–2142. doi: 10.1056/nejmoa070596. PubMed DOI

Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.-L., Dmoszynska A., Miguel J.S., Hellmann A., Facon T., Foà R., et al. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 2007;357:2123–2132. doi: 10.1056/nejmoa070594. PubMed DOI

Gay F., Hayman S.R., Lacy M.Q., Buadi F., Gertz M.A., Kumar S., Dispenzieri A., Mikhael J.R., Bergsagel P.L., Dingli D., et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: A comparative analysis of 411 patients. Blood. 2010;115:1343–1350. doi: 10.1182/blood-2009-08-239046. PubMed DOI PMC

Rajkumar S.V., Hayman S.R., Lacy M.Q., Dispenzieri A., Geyer S.M., Kabat B., Zeldenrust S.R., Kumar S., Greipp P.R., Fonseca R., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050–4053. doi: 10.1182/blood-2005-07-2817. PubMed DOI PMC

Rajkumar S.V., Jacobus S., Callander N.S., Fonseca R., Vesole D.H., E Williams M., Abonour R., Siegel D.S., Katz M., Greipp P.R. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37. doi: 10.1016/s1470-2045(09)70284-0. PubMed DOI PMC

Van Beurden-Tan C.H.Y., Franken M.G., Blommestein H.M., Groot C.A.U.-D., Sonneveld P. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. J. Clin. Oncol. 2017;35:1312–1319. doi: 10.1200/jco.2016.71.1663. PubMed DOI

Richardson P.G., Xie W., Jagannath S., Jakubowiak A., Lonial S., Raje N.S., Alsina M., Ghobrial I.M., Schlossman R.L., Munshi N.C., et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123:1461–1469. doi: 10.1182/blood-2013-07-517276. PubMed DOI PMC

Stewart A.K., Rajkumar S.V., Dimopoulos M.A., Masszi T., Špička I., Oriol A., Hájek R., Rosiñol L., Siegel D.S., Mihaylov G.G., et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New Engl. J. Med. 2015;372:142–152. doi: 10.1056/nejmoa1411321. PubMed DOI

Lonial S., Dimopoulos M., Palumbo A., White D., Grosicki S., Spicka I., Walter-Croneck A., Moreau P., Mateos M.V., Magen H., et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 2015;373:621–631. doi: 10.1056/nejmoa1505654. PubMed DOI

Dimopoulos M.A., San-Miguel J., Belch A., White D., Benboubker L., Cook G., Leiba M., Morton J., Ho P.J., Kim K., et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX. Haematologica. 2018;103:2088–2096. doi: 10.3324/haematol.2018.194282. PubMed DOI PMC

Facon T., Kumar S., Plesner T., Orlowski R.Z., Moreau P., Bahlis N., Basu S., Nahi H., Hulin C., Quach H., et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N. Engl. J. Med. 2019;380:2104–2115. doi: 10.1056/nejmoa1817249. PubMed DOI PMC

Attal M., Lauwers-Cances V., Marit G., Caillot D., Moreau P., Facon T., Stoppa A.M., Hulin C., Benboubker L., Garderet L., et al. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. N. Engl. J. Med. 2012;366:1782–1791. doi: 10.1056/nejmoa1114138. PubMed DOI

Zhu Y.X., Kortuem K.M., Stewart A.K. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk. Lymphoma. 2012;54:683–687. doi: 10.3109/10428194.2012.728597. PubMed DOI PMC

McCurdy A.R., Lacy M.Q. Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: An update for the hematologist. Ther. Adv. Hematol. 2013;4:211–216. doi: 10.1177/2040620713480155. PubMed DOI PMC

Miguel J.S., Weisel K., Moreau P., Lacy M., Song K., Delforge M., Karlin L., Goldschmidt H., Banos A., Oriol A., et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066. doi: 10.1016/s1470-2045(13)70380-2. PubMed DOI

Richardson P.G., Oriol A., Beksac M., Liberati A.M., Galli M., Schjesvold F., Lindsay J., Weisel K., White D., Facon T., et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781–794. doi: 10.1016/s1470-2045(19)30152-4. PubMed DOI

Dimopoulos M.A., Dytfeld D., Grosicki S., Moreau P., Takezako N., Hori M., Leleu X., Leblanc R., Suzuki K., Raab M.S., et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 2018;379:1811–1822. doi: 10.1056/nejmoa1805762. PubMed DOI

Attal M., Richardson P.G., Rajkumar S.V., San-Miguel J., Beksac M., Spicka I., Leleu X., Schjesvold F., Moreau P., Dimopoulos M.A., et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096–2107. doi: 10.1016/s0140-6736(19)32556-5. PubMed DOI

Chari A., Suvannasankha A., Fay J.W., Arnulf B., Kaufman J.L., Ifthikharuddin J.J., Weiss B.M., Krishnan A., Lentzsch S., Comenzo R., et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130:974–981. doi: 10.1182/blood-2017-05-785246. PubMed DOI PMC

Holstein S.A., McCarthy P.L. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Drugs. 2017;77:505–520. doi: 10.1007/s40265-017-0689-1. PubMed DOI PMC